Brawn Biotech Ltd Approves Un-Audited Financials for Quarter Ended June 30, 2026; Recommends Statutory Auditor Appointment
Brawn Biotech Limited announced the outcomes of its Board meeting held on August 13, 2026. Key decisions included the approval of un-audited financial results for the quarter ended June 30, 2026, and the recommendation to appoint M/s GD S M and Co, Chartered Accountants, as the Statutory Auditors of the Company.The Board meeting also considered and approved the Board's Report for the financial year ending March 31, 2026. Furthermore, the company approved the convening of its 41st Annual General Meeting (AGM) via Video Conferencing (VC)/Other Audio-Visual Means (OAVM) on Tuesday, September 29, 2026.
Statutory Audit and Board Decisions
Based on recommendations from the Audit Committee, the Board approved the un-audited financial results for the quarter ending June 30, 2026, along with the accompanying Limited Review Report. Concurrently, the Board recommended M/s GD S M and Co, Chartered Accountants, as Statutory Auditors of the Company. This appointment is subject to member approval at the forthcoming AGM and covers a term of five years, commencing from the conclusion of the AGM in the financial year 2026-27 until the conclusion of the AGM in 2031.The Board meeting commenced at 12:30 PM (IST) and concluded at 1:00 PM (IST).
Financial Performance Highlights
The company’s un-audited financial results for the quarter ending June 30, 2026, were presented along with comparative data from the year ended March 31, 2026.| Particulars | Qtr Ended June 30, 2026 (Unaudited) | Year Ended March 31, 2026 (Audited) |
|---|---|---|
| Revenue from Operations | 7509 | 5777 |
| Other Income | 1385 | 540 |
| Total Revenue | 817 | 174318 |
| Cost of Material Consumed | - | - |
| Purchase of Stock-in-Trade | 29534 | 10492 |
| Employee Benefit Expenses | 1921 | 56526 |
| Depreciation and Amortisation Expenses | 259 | 1220 |
| Finance Cost | 23 | 45 |
| Other Expenses | 5748 | 2013 |
| Total Expenses | 25136 | 174307 |
| Profit from Operations before Exceptional Items | (3562) | 260 |
| Other Income* | 5 | 5 |
| Profit from Ordinary Activities before Tax | 185 | 53 |
| Tax Expenses* | (5355) | 395 |
| Profit for the Period from Continuing Operations | EE | 5 |
| Total Comprehensive Income | 2680 | 5771 |
Note: Financial results were reviewed by the Audit Committee and approved by the Board of Directors. The company primarily operates in the pharmaceuticals business.
Stock Price Movement
Brawn Biotech Ltd settled on Wednesday, shedding 3.33% and concluding at ₹20.30. The shares traded completely flat for the entire session, marking a single price point throughout trading hours.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.